Alligator Bioscience AB
STO:ATORX
Balance Sheet
Balance Sheet Decomposition
Alligator Bioscience AB
Alligator Bioscience AB
Balance Sheet
Alligator Bioscience AB
| Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||
| Cash & Cash Equivalents |
37
|
366
|
659
|
473
|
363
|
197
|
103
|
278
|
97
|
66
|
64
|
62
|
|
| Cash |
37
|
366
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Cash Equivalents |
0
|
0
|
659
|
473
|
363
|
197
|
103
|
278
|
97
|
66
|
64
|
62
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
20
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
0
|
4
|
12
|
57
|
30
|
5
|
5
|
14
|
18
|
5
|
4
|
4
|
|
| Accounts Receivables |
0
|
1
|
0
|
53
|
26
|
0
|
0
|
7
|
14
|
0
|
1
|
0
|
|
| Other Receivables |
0
|
3
|
12
|
4
|
5
|
5
|
5
|
7
|
4
|
5
|
4
|
4
|
|
| Other Current Assets |
0
|
1
|
5
|
3
|
4
|
4
|
2
|
7
|
8
|
8
|
3
|
3
|
|
| Total Current Assets |
0
|
370
|
676
|
533
|
418
|
206
|
110
|
300
|
123
|
78
|
71
|
69
|
|
| PP&E Net |
0
|
2
|
4
|
16
|
18
|
33
|
23
|
15
|
27
|
20
|
3
|
2
|
|
| PP&E Gross |
0
|
2
|
4
|
16
|
18
|
33
|
23
|
15
|
27
|
20
|
3
|
0
|
|
| Accumulated Depreciation |
0
|
8
|
9
|
11
|
15
|
26
|
37
|
49
|
61
|
68
|
127
|
0
|
|
| Intangible Assets |
0
|
43
|
20
|
19
|
19
|
19
|
18
|
18
|
18
|
18
|
28
|
40
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
2
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
74
|
53
|
53
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
0
N/A
|
416
N/A
|
701
+68%
|
643
-8%
|
508
-21%
|
311
-39%
|
152
-51%
|
333
+119%
|
170
-49%
|
118
-30%
|
104
-12%
|
111
+6%
|
|
| Liabilities | |||||||||||||
| Accounts Payable |
0
|
5
|
13
|
14
|
18
|
16
|
7
|
9
|
13
|
21
|
4
|
5
|
|
| Accrued Liabilities |
0
|
14
|
11
|
10
|
20
|
17
|
16
|
23
|
39
|
65
|
46
|
28
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
6
|
6
|
6
|
8
|
9
|
10
|
9
|
|
| Other Current Liabilities |
0
|
1
|
1
|
1
|
2
|
2
|
2
|
9
|
4
|
4
|
141
|
36
|
|
| Total Current Liabilities |
0
|
19
|
25
|
25
|
40
|
41
|
31
|
47
|
65
|
99
|
201
|
78
|
|
| Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
11
|
6
|
4
|
16
|
8
|
33
|
26
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
0
N/A
|
19
N/A
|
25
+27%
|
25
+2%
|
40
+59%
|
53
+32%
|
37
-30%
|
51
+39%
|
81
+58%
|
107
+32%
|
235
+120%
|
104
-56%
|
|
| Equity | |||||||||||||
| Common Stock |
0
|
24
|
28
|
29
|
29
|
29
|
29
|
88
|
89
|
42
|
1
|
99
|
|
| Retained Earnings |
0
|
38
|
10
|
73
|
223
|
433
|
576
|
718
|
911
|
1 086
|
1 278
|
1 303
|
|
| Additional Paid In Capital |
0
|
335
|
658
|
663
|
663
|
663
|
663
|
912
|
912
|
1 055
|
1 147
|
1 210
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
0
N/A
|
397
N/A
|
676
+70%
|
618
-9%
|
468
-24%
|
258
-45%
|
115
-55%
|
282
+145%
|
89
-68%
|
12
-87%
|
131
N/A
|
7
N/A
|
|
| Total Liabilities & Equity |
0
N/A
|
416
N/A
|
701
+68%
|
643
-8%
|
508
-21%
|
311
-39%
|
152
-51%
|
333
+119%
|
170
-49%
|
118
-30%
|
104
-12%
|
111
+6%
|
|
| Shares Outstanding | |||||||||||||
| Common Shares Outstanding |
1
|
1
|
2
|
2
|
2
|
2
|
2
|
4
|
5
|
9
|
10
|
44
|
|